Proteomics studies the complete set of proteins expressed by a cell, tissue, or organism, providing a more dynamic and functional view of biology than genomics alone. While the genome is essentially fixed, the proteome changes continuously in response to disease, environment, and treatment, making it a richer source of diagnostic and therapeutic insight. Mass spectrometry-based proteomics can now measure thousands of proteins simultaneously, and newer affinity-based platforms (SomaScan, Olink) provide high-throughput protein measurement at lower cost. The sector serves drug target discovery (identifying disease-relevant proteins), diagnostic development (protein biomarkers for disease detection), companion diagnostics (predicting treatment response), and the emerging category of multi-omic integration (combining proteomic data with genomics, metabolomics, and clinical data for comprehensive patient profiling).

Key Investors

No items found.

Key Programs

We couldn't find any relevant programs. Check back soon.

Key Hubs

No items found.

Other Sectors